If the resulting β cell-like cells are capable of glucose-regulated insulin secretion, they might be able to compensate in pancreatic cancer patients the insulin deficiency resulting from radical surgery or a long-term history of type II diabetes. The gene discussed is INS; the disease is familial pancreatic carcinoma.